- Previous Close
1.2300 - Open
1.2300 - Bid 0.8856 x 200
- Ask 1.5700 x 200
- Day's Range
1.2200 - 1.2399 - 52 Week Range
0.8400 - 7.8000 - Volume
15,768 - Avg. Volume
88,800 - Market Cap (intraday)
67.418M - Beta (5Y Monthly) 3.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4600 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
www.vivani.comRecent News: VANI
View More
Performance Overview: VANI
Trailing total returns as of 9/23/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VANI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VANI
View MoreValuation Measures
Market Cap
67.96M
Enterprise Value
63.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.85
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.93
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.29%
Return on Equity (ttm)
-86.10%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.2M
Diluted EPS (ttm)
-0.4600
Balance Sheet and Cash Flow
Total Cash (mrq)
24.92M
Total Debt/Equity (mrq)
84.10%
Levered Free Cash Flow (ttm)
-14.29M
Research Analysis: VANI
View MoreCompany Insights: VANI
VANI does not have Company Insights
Research Reports: VANI
View MoreDaily – Vickers Top Insider Picks for 03/18/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/15/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/14/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/13/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.